Arax Advisory Partners’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $42.5K | Buy |
81
+19
| +31% | +$9.98K | ﹤0.01% | 1316 |
|
|
2025
Q1 | $39.3K | Buy |
62
+48
| +343% | +$30.4K | ﹤0.01% | 1044 |
|
|
2024
Q4 | $9.97K | Sell |
14
-28
| -67% | -$19.9K | ﹤0.01% | 1493 |
|
|
2024
Q3 | $44.2K | Hold |
42
| – | – | ﹤0.01% | 767 |
|
|
2024
Q2 | $44.1K | Buy |
42
+28
| +200% | +$29.4K | ﹤0.01% | 707 |
|
|
2024
Q1 | $13.5K | Hold |
14
| – | – | ﹤0.01% | 731 |
|
|
2023
Q4 | $12.3K | Sell |
14
-1
| -7% | -$878 | ﹤0.01% | 732 |
|
|
2023
Q3 | $12.3K | Buy |
15
+1
| +7% | +$823 | ﹤0.01% | 675 |
|
|
2023
Q2 | $10.1K | Sell |
14
-1
| -7% | -$719 | ﹤0.01% | 705 |
|
|
2023
Q1 | $12.3K | Buy |
15
+4
| +36% | +$3.29K | ﹤0.01% | 656 |
|
|
2022
Q4 | $7.94K | Buy |
11
+1
| +10% | +$721 | ﹤0.01% | 683 |
|
|
2022
Q3 | $7K | Buy |
10
+6
| +150% | +$4.2K | ﹤0.01% | 723 |
|
|
2022
Q2 | $2K | Buy |
4
+2
| +100% | +$1K | ﹤0.01% | 962 |
|
|
2022
Q1 | $1K | Sell |
2
-2
| -50% | -$1K | ﹤0.01% | 1079 |
|
|
2021
Q4 | $3K | Buy |
4
+2
| +100% | +$1.5K | ﹤0.01% | 844 |
|
|
2021
Q3 | $1K | Buy |
+2
| New | +$1K | ﹤0.01% | 934 |
|
|
2018
Q3 | – | Sell |
-10
| Closed | -$3K | – | 710 |
|
|
2018
Q2 | $3K | Sell |
10
-11
| -52% | -$3.3K | ﹤0.01% | 426 |
|
|
2018
Q1 | $7K | Sell |
21
-65
| -76% | -$21.7K | ﹤0.01% | 350 |
|
|
2017
Q4 | $32K | Sell |
86
-11
| -11% | -$4.09K | 0.01% | 245 |
|
|
2017
Q3 | $43K | Sell |
97
-10
| -9% | -$4.43K | 0.02% | 227 |
|
|
2017
Q2 | $53K | Buy |
107
+56
| +110% | +$27.7K | 0.03% | 222 |
|
|
2017
Q1 | $19K | Buy |
51
+45
| +750% | +$16.8K | 0.01% | 285 |
|
|
2016
Q4 | $2K | Buy |
+6
| New | +$2K | ﹤0.01% | 483 |
|